Thank you, Madam Chair.
If you're looking for a canary, I can always volunteer my colleague here, David.
I'm going to show my Manitoba bias by asking Ms. Boscoe several questions. I'll ask them all at once, and then my time will be up, I'm sure.
The HPV issue is something the government takes very seriously. We invested $300 million in the vaccine. I am intrigued by one of the statements you made right off the bat, and that was--I hope I wrote it down correctly--“They die of lack of care, not of the disease”. I wonder if you could expand on what that actually means. Perhaps the vaccine isn't the whole solution. If you were to take the vaccine and also follow up with diligent care, that would reduce the mortality rate significantly, I would hope. I'd like to hear your point of view on that.
Also, in your opening statement you mentioned that you co-chaired a committee on Infoway. I think everyone agrees that there's an importance in post-market surveillance; it's the mechanisms on how to do that....
Do you have any insight or recommendations for this committee that we could put in our report that deal with Infoway or e-pharmacy or e-health records, insight or recommendations that would allow data mining or make it easier for medical practitioners to report? Four hours on one issue is a long time. You could see a lot of patients in that time, and you're probably not getting compensated for the time you're spending on reporting. Are there ways through Infoway and e-technology to make this an easier process? You seem to be in a good position to comment on that, given your background.
Those are my questions.